Entero Therapeutics (Nasdaq:ENTO) - Cotización, noticias y análisis

Resumen de acción ENTO

Entero Therapeutics, Inc. es una empresa biofarmacéutica en fase clínica dedicada al desarrollo de terapias dirigidas y administradas por vía oral para el tratamiento de pacientes con enfermedades gastrointestinales. Saber más

Análisis fundamental de ENTO
Puntuación del snowflake
Valoración	2/6
Crecimiento futuro	0/6
Rendimiento pasado	0/6
Salud financiera	4/6
Dividendos	0/6

Recompensas

Los beneficios han crecido un 16.2% al año en los últimos 5 años

Análisis de riesgos

Tiene unos ingresos inferiores a 1 millón de dólares ($0)

Los accionistas han sido diluidos sustancialmente en el último año

Tiene menos de 1 año de cash runway

No tiene una capitalización de mercado significativa ($2M)

+ 2 riesgos adicionales

Competidores de Entero Therapeutics, Inc.

Sonnet BioTherapeutics Holdings

NasdaqCM:SONN

US$2.3m

GRI Bio

NasdaqCM:GRI

US$2.1m

Scorpius Holdings

NYSEAM:SCPX

US$2.8m

Salarius Pharmaceuticals

NasdaqCM:SLRX

US$2.2m

Historial de precios y rendimiento

Resumen de todos los máximos históricos, cambios y caídas de precios de Entero Therapeutics
Precios históricos de las acciones
Precio actual de la acción	US$0.45
Máximo en las últimas 52 semanas	US$14.51
Mínimo de 52 semanas	US$0.18
Beta	1.22
1Cambio en 1 mes	-21.49%
Variación en 3 meses	8.98%
Cambio de 1 año	-90.53%
3Variación en 3 años	-99.99%
Variación en 5 años	-100.00%
Variación desde la OPV	-100.00%

Noticias y actualizaciones recientes

Recent updates

First Wave BioPharma announces pricing of $6.0 million public offering

Oct 07

First Wave BioPharma extends selloff after announcing strategic shift

Sep 19

First Wave stock slips ~21% on plans for amended FDA application for enzyme adrulipase

Sep 07

First Wave BioPharma announces 1-for-30 reverse stock split

Aug 25

First Wave BioPharma to raise capital in convertible preferred stocks offering

Jul 15

First Wave BioPharma Set For New Growth Trajectory With GI Pipeline Expansion De-Risking The Investment

Oct 19

Rentabilidad de los accionistas

	ENTO	US Biotechs	Mercado US
7D	13.3%	4.3%	1.6%
1Y	-90.5%	18.8%	32.3%

Rentabilidad vs. Industria: Los resultados de ENTO fueron inferiores a los de la industria US Biotechs, que obtuvo un rendimiento del 18.8% el año pasado.

Rentabilidad vs. Mercado: ENTO obtuvo unos resultados inferiores a los del mercado US, que fueron del 32.3% el año pasado.

Volatilidad de los precios

Is ENTO's price volatile compared to industry and market?
ENTO volatility
ENTO Average Weekly Movement	27.7%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	3.1%

Precio estable de las acciones: El precio de las acciones de ENTO ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de ENTO(28%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de las acciones de US.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2014	9	James Sapirstein	www.enterothera.com

Entero Therapeutics, una empresa biofarmacéutica en fase clínica, se dedica al desarrollo de terapias dirigidas y administradas por vía oral para el tratamiento de pacientes con enfermedades gastrointestinales. Entre sus productos en fase de desarrollo figuran la latiglutenasa, un bioterapéutico oral dirigido contra la celiaquía diseñado para descomponer el gluten en péptidos no inmunogénicos, actualmente en estudios de fase 2; y el capeserod, un agonista parcial selectivo del receptor 5-HT4 en estudios de fase 1 para el tratamiento de la gastroparesia. También participa en el desarrollo de adrulipasa, una enzima lipasa recombinante diseñada para permitir la digestión de grasas y otros nutrientes, actualmente en estudios de fase 2 para el tratamiento de la insuficiencia pancreática exocrina en pacientes con fibrosis quística y pancreatitis crónica; y niclosamida, una pequeña molécula oral con tratamiento inhibidor antiinflamatorio, actualmente en estudios de fase 2 para el tratamiento de la proctitis ulcerosa y la proctosigmoiditis ulcerosa, así como la colitis asociada a inhibidores de puntos de control inmunitarios y la diarrea en pacientes con cáncer metastásico.

Resumen de fundamentos de Entero Therapeutics, Inc.

¿Cómo se comparan los beneficios e ingresos de Entero Therapeutics con su capitalización de mercado?
Estadísticas fundamentales de ENTO
Capitalización bursátil	US$2.21m
Beneficios(TTM)	-US$8.15m
Ingresos (TTM)	n/a

0.0x

Ratio precio-ventas (PS)

-0.3x

Ratio precio-beneficio (PE)

¿Está ENTO sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de ENTO
Ingresos	US$0
Coste de los ingresos	US$0
Beneficio bruto	US$0
Otros gastos	US$8.15m
Beneficios	-US$8.15m

Últimos beneficios comunicados

Sep 30, 2024

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-1.71
Margen bruto	0.00%
Margen de beneficio neto	0.00%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado ENTO a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción ENTO

Recompensas

Análisis de riesgos

Competidores de Entero Therapeutics, Inc.

NasdaqCM:SONN

US$2.3m

NasdaqCM:GRI

US$2.1m

NYSEAM:SCPX

US$2.8m

NasdaqCM:SLRX

US$2.2m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Less than half of directors are independent

Journey Therapeutics, Inc. entered into a binding term sheet to acquire Entero Therapeutics, Inc. (NasdaqCM:ENTO) in a reverse merger transaction.

Entero Therapeutics Receives Non-Compliance Notice Regarding Nasdaq Listing Rule 5550(a)(2)

Entero Therapeutics Receives Nasdaq Notification Regarding Delayed Form 10-Q

Entero Therapeutics, Inc. announced delayed 10-Q filing

Entero Therapeutics Notifies the Nasdaq Stock Market of its Non-Compliance with Nasdaq Rule 5605(c)(2)

Recent updates

Less than half of directors are independent

Journey Therapeutics, Inc. entered into a binding term sheet to acquire Entero Therapeutics, Inc. (NasdaqCM:ENTO) in a reverse merger transaction.

Entero Therapeutics Receives Non-Compliance Notice Regarding Nasdaq Listing Rule 5550(a)(2)

Entero Therapeutics Receives Nasdaq Notification Regarding Delayed Form 10-Q

Entero Therapeutics, Inc. announced delayed 10-Q filing

Entero Therapeutics Notifies the Nasdaq Stock Market of its Non-Compliance with Nasdaq Rule 5605(c)(2)

First Wave BioPharma, Inc.(NasdaqGM:ENTO) dropped from NASDAQ Composite Index

First Wave BioPharma, Inc. has filed a Follow-on Equity Offering in the amount of $0.9882 million.

First Wave BioPharma, Inc. (NasdaqCM:FWBI) completed the acquisition of ImmunogenX, LLC for approximately $3 million.

First Wave BioPharma, Inc. (NasdaqCM:FWBI) completed the acquisition of ImmunogenX, LLC for approximator $3 million.

First Wave BioPharma, Inc. has filed a Follow-on Equity Offering in the amount of $4.000006 million.

First Wave BioPharma, Inc. has withdrawn its Follow-on Equity Offering.

First Wave BioPharma, Inc. (NasdaqCM:FWBI) signed a non-binding term sheet to acquire ImmunogenX, LLC.

First Wave BioPharma, Inc. has filed a Follow-on Equity Offering.

First Wave Biopharma, Inc. Receives Written Notice from the Listing Qualifications Department of the Nasdaq Stock Market

First Wave BioPharma Receives Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market

First Wave BioPharma Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement Under Listing Rule 5550(b)(1)

First Wave BioPharma, Inc. Announces Initial Topline Results from Phase 2 Span Clinical Trial Investigating Enhanced Adrulipase Formulation

New major risk - Share price stability

First Wave Biopharma Completes Patient Screening for Phase 2 Span Adrulipase Clinical Trial in Cystic Fibrosis

First Wave BioPharma Regains Compliance with Nasdaq’s Minimum Bid Price Requirement

First Wave BioPharma Announces First Patient Screened for Phase 2 SPAN Adrulipase Trial in Cystic Fibrosis

First Wave BioPharma Announces Initiation of Phase 2 Trial Investigating Enhanced Adrulipase Formulation in Exocrine Pancreatic Insufficiency in Patients with Cystic Fibrosis

First Wave BioPharma, Inc. Announces Expansion of Adrulipase Intellectual Property Portfolio

First Wave BioPharma, Inc. Provides Update on IND Filing for Phase 2 Trial of Enhanced Microgranule Formulation of Adrulipase for Exocrine Pancreatic Insufficiency

First Wave BioPharma Receives A Deficiency Notice from the Listing Qualifications Staff of Nasdaq Regarding Minimum Bid Price

First Wave BioPharma, Inc. Announces Initial Clinical Sites for its Phase 2 Trial of Enhanced Microgranule Delivery Formulation of Adrulipase

First Wave BioPharma Files Investigational New Drug Application for Enhanced Microgranule Delivery Formulation of Adrulipase

First Wave BioPharma, Inc. Presents Research Demonstrating Benefits of Improved Adrulipase Drug Delivery Formulation at AAPS 2022 PharmSci 360

First Wave BioPharma, Inc. has completed a Follow-on Equity Offering in the amount of $6.000001 million.

First Wave BioPharma announces pricing of $6.0 million public offering

First Wave BioPharma, Inc. Provides Update on Clinical Programs

First Wave BioPharma extends selloff after announcing strategic shift

First Wave BioPharma, Inc. Finalizes Selection of Adrulipase Microgranule Drug Delivery Formulation

First Wave stock slips ~21% on plans for amended FDA application for enzyme adrulipase

First Wave BioPharma Announces Reverse Stock Split

First Wave BioPharma announces 1-for-30 reverse stock split

Price target decreased to US$9.00

High number of new and inexperienced directors

First Wave BioPharma, Inc., Annual General Meeting, Aug 25, 2022

First Wave BioPharma to raise capital in convertible preferred stocks offering

First Wave Biopharma, Inc Announces Resignation from the Board of Directors

First Wave BioPharma, Inc. announced delayed 10-Q filing

First Wave BioPharma, Inc. Appoints David Hoffman as Member of the Board

Price target decreased to US$20.00

High number of new and inexperienced directors

James Pennington Announces His Intention to Retire as Chief Medical Officer of First Wave BioPharma, Inc

First Wave BioPharma, Inc. Files U.S. and PCT Patent Applications for Niclosamide in Long-Haul COVID-19

First Wave Biopharma, Inc. Announce Chief Financial Officer Changes

First Wave BioPharma, Inc. Provides Update on Adrulipase (FW-EPI) Clinical Program

First Wave BioPharma, Inc. Completes Enrollment for Part 2 of RESERVOIR Phase 2 Trial Evaluating FW-COV in COVID-19-Related GI Infections

High number of new directors

First Wave BioPharma Receives A Letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC

First Wave BioPharma Set For New Growth Trajectory With GI Pipeline Expansion De-Risking The Investment

First Wave BioPharma Begins Patient Screening for Phase 2b Clinical Trial Evaluating Niclosamide in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis

Price target decreased to US$25.00

AzurRx BioPharma, Inc. (NasdaqCM:AZRX) agreed to acquire First Wave Bio, Inc. for $230 million.

AzurRx BioPharma, Inc. Announces Positive Results from Independent Data Monitoring Committee Review of Safety Data from Part 1 of RESERVOIR Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections

AzurRx BioPharma Submits an Investigational New Drug Application for Niclosamide as Treatment for Grade 1 and Grade 2 Immune Checkpoint Inhibitor-Associated Colitis